A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification.

@article{Zhu2018ASO,
  title={A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification.},
  author={Hanting Zhu and Chunyu Wang and Jingjing Wang and Dawei Chen and Jiaying Deng and Jia-Peng Deng and Jian-hong Fan and Harun Badakhshi and Xuesong Huang and Likun Zhang and Jie Cai and Shengyue Guo and Wubin Qian and Yongzhan Nie and Qi-xiang Li and Kuaile Zhao},
  journal={Journal of thoracic disease},
  year={2018},
  volume={10 9},
  pages={
          5328-5338
        }
}
Background Epidermal growth factor receptor (EGFR) is reportedly overexpressed in most esophageal tumors, but most targeted therapies showed no efficacy in non-selected patients. This study aims at investigating the adaptive cetuximab subset in a cohort of esophageal squamous cell carcinoma (ESCC) patient-derived xenografts (PDXs). Methods A large panel of ESCC PDXs has been established. The copy number, mRNA expression and immunohistochemistry (IHC) of key EGFR pathways have been examined… 

Figures and Tables from this paper

Loss of p120ctn causes EGFR-targeted therapy resistance and failure
TLDR
Using human esophageal keratinocytes, it is found that EGFR-targeting compounds are toxic to cells overexpressing EGFR, and data suggest that decreased p120ctn causes resistance to EGFR therapy.
Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed
TLDR
EGFR CNG in gastroesophageal cancer patients was associated with improved overall survival following fluoropyrimidine/platinum chemotherapy, however, co-administration of gefitinib and oxaliplatin or cisplatin was frequently antagonistic in cell-based assays in EGFR C NG ESCC, whereas the combination ofgefit inib with docetaxel or irinotecan was more efficacious.
Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers
TLDR
PDX models of EC (EC-PDX) provide fine platforms to investigate the tumor microenvironment, tumor genomic heterogeneity, and tumor response to chemoradiotherapy, which are necessary for new drug discovery to combat EC in addition to optimization of current therapeutic strategies for EC.
Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas
TLDR
New molecular analyses suggest that HRAS may also be important in some HNSCC cases where it is not mutated, which might allow tipifarnib to be active in a broader population of H NSCC patients when used in combination with other agents such as cisplatin, cetuximab, or alpelisib.
PTK7, a Catalytically Inactive Receptor Tyrosine Kinase, Increases Oncogenic Phenotypes in Xenograft Tumors of Esophageal Squamous Cell Carcinoma KYSE-30 Cells
TLDR
It is proposed that PTK7 plays an important role in the tumorigenesis of ESCC cells in vivo and is a potential therapeutic target for ESCC.
Translational and Clinical Relevance of PDX‐Derived Organoid Models in Oncology Drug Discovery and Development
TLDR
This overview summarizes the generation of matched in vitro/in vivo models from patient material, the advantages over other systems, and the applications to drug discovery.
A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer
TLDR
Evaluating the anti-tumor efficacy of the epidermal growth factor receptor (EGFR)-targeting recombinant fusion protein Fv-LDP-D3 and its antibody-drug conjugate suggests their potential as promising candidates for targeted therapy against esophageal cancer.
...
...

References

SHOWING 1-10 OF 39 REFERENCES
Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma
TLDR
It is suggested that EGFR overexpression might potentially be used in predicting the efficacy in patients treated with Icotinib, and has implications for both clinical trial design and therapeutic strategies.
High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis
TLDR
A hypothesis is put forward that high EGFR and low p-Akt expression may predict a clinical benefit of EGFR antagonists such as nimotuzumab combined with RT or CRT and can be further tested in larger groups of patients.
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
TLDR
Genome-wide profiling and additional investigations suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.
Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature
TLDR
The data seem to suggest that an mRNA expressing signature may also be developed as a predictive biomarker for drug response, similarly to genetic mutations, for cetuximab response.
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
TLDR
EGFR CNG assessed by FISH appears to identify a subgroup of patients with esophageal cancer who may benefit from gefitinib as a second-line treatment, and anti-EGFR therapies should be investigated in prospective clinical trials in different settings in EGFR FISH-positive and, in particular, EGFR-amplified esophagal cancer.
A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations
TLDR
The data seem to suggest that a set of the six-oncogenic alleles may be of better predictive value than the current practiced stratification in the cetuximab CRC treatment, justifying a new prospective clinical investigation on an independent cohort for confirmation.
Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
TLDR
An extensive panel of patient-derived NSCLC xenograft models useful for the testing of novel compounds and for the identification of biomarkers is established and provides appropriate models for testing marketed as well as novel drug candidates.
Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patients
TLDR
A panel of patient‐derived xenografts from treatment naïve Asian NSCLC patients, including those containing “classic” EGFR activating mutations, are established, offering novel practical approaches to overcome the two most common resistances to EGFR‐TKIs seen in the clinic using marketed target therapies.
Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice
TLDR
PYM could down-regulate the expression of EGFR in esophageal cancer cells and potentiate the effects of cetuximab on esophagal cancer xenograft in nude mice and the combination of PYM and cetUXimab, the EGFR-targeted combination of a chemotherapeutic agent and an antibody-based drug, might be useful in cancer therapy.
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
TLDR
Gefitinib has a modest activity in second-line treatment of advanced esophageal cancer, however, the patient outcome was significantly better in female patients and in patients demonstrating high EGFR expression or SCC histology.
...
...